Eiken Chemical Co., Ltd. (4549) AI Stock Analysis

• Market Cap: ¥96.14B
• Dividend Yield: 2.31%
• Average Volume (3M): 72.32K
• Price to Earnings (P/E): 26.7
• Beta (1Y): 0.64
• Revenue Growth: 4.36%
• EPS Growth: 79.43%
• Country: JP
• Employees: 757
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 22.51
• Shares Outstanding: 34,541,440
• 10 Day Avg. Volume: 81,940
• 30 Day Avg. Volume: 72,320
• PEG Ratio: -3.65
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 1.92
• P/FCF Ratio: 95.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 106.9
• Revenue Forecast (FY): ¥42.20B

• Rating: 68 Neutral
• Price Target: ¥3,133.00 ▲(30.16% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is supported primarily by a strong, low-leverage balance sheet and generally stable operating performance, but is held back by declining profitability and weakening free cash flow. Technically, the uptrend is intact, yet extremely overbought momentum raises near-term risk, and valuation (P/E 26.24 with ~1.70% yield) is not especially attractive.

Positive Factors

Balance Sheet Strength

Very low leverage and a high equity ratio provide durable financial flexibility. This capital structure reduces refinancing and interest-rate risks, supports investment or M&A optionality, and cushions the business through demand cycles over the next 2–6 months and beyond.

Recurring Consumables Revenue

A consumables-driven IVD model creates predictable, repeat purchase demand tied to testing volumes. Installed-base pull-through and sticky lab relationships deliver steady revenue and cash visibility, underpinning durable topline resilience and long-term margin support.

Cash Conversion Quality

Strong conversion of reported profits into operating cash indicates high earnings quality and provides internal funding for working capital, R&D and maintenance capex. This reduces reliance on debt and supports stable operations and strategic investments.

Negative Factors

Declining Profitability

Falling net margin and reduced ROE point to weaker profitability and shareholder returns. If margin compression persists due to pricing, cost inflation, or mix shifts, it will limit retained earnings, slow reinvestment capacity, and pressure long-term return metrics.

Weakened Free Cash Flow

A sharp decline in FCF after capex reduces cash available for dividends, strategic initiatives, or bolt-on investments. Persistently weak FCF increases sensitivity to earnings shocks and could force tougher capital allocation choices despite a strong balance sheet.

Modest Revenue Growth

Very low top-line growth suggests limited market expansion or competitive pressures. Over time, slow revenue expansion constrains operating leverage, making it harder to lift margins and ROE materially without new products, market share gains, or geographic diversification.

Eiken Chemical Co., Ltd. Business Overview & Revenue Model

Company Description

Eiken Chemical Co., Ltd. manufactures and sells clinical diagnostics and equipment in Japan. The company is involved in developing clinical diagnostic aids to various aspects of contemporary medicine, including biochemical, immunological, serological, dry chemical diagnosis, and automatic analyzers. It also develops and supplies OC-SENSOR, an automated immunochemical fecal test for detecting gastrointestinal bleeding associated with disorders, such as colorectal cancer, polyps, and diverticulitis. In addition, the company offers real-time turbidi meters, and homeothermal equipment; amplification kits and fluorescence detection reagents for research use; and detection kits. Further, it manufactures a range of products that are used in the field of microbiology; and provides other products comprising immunological and serological reagents. The company was formerly known as Nihon Eiyokagaku Co., Ltd. and changed its name to Eiken Chemical Co., Ltd. in 1969. Eiken Chemical Co., Ltd. was founded in 1939 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Eiken Chemical primarily makes money by selling in vitro diagnostic (IVD) products used by clinical laboratories and healthcare institutions. Its core revenue stream is the sale of diagnostic reagents and test kits consumed in routine and specialized testing; these are typically recurring purchases because each test requires fresh consumables. A second revenue stream comes from diagnostic instruments/systems used to run certain assays, where revenue is generated either through direct sales of equipment and/or the pull-through effect of ongoing reagent demand tied to the installed base (specific commercial structures beyond this general model are null). The company also earns revenue from related services and support activities connected to deploying and maintaining its diagnostic solutions (e.g., technical support and other ancillary offerings; the exact breakdown is null). Additional earnings may come from overseas sales and distribution of its diagnostics portfolio outside Japan, depending on product registrations and channel access in each market (country-by-country contributions and material partnerships are null).

Eiken Chemical Co., Ltd. Financial Statement Overview

Summary

Financials are stable overall: modest revenue growth (+1.22%) and a very strong balance sheet (low leverage with 0.10 debt-to-equity and ~69.9% equity ratio). Offsetting this, profitability is weakening (net margin down to 5.50% and ROE down to 5.11%), and free cash flow metrics have deteriorated (FCF to net income down to 0.36 with sharply lower FCF growth).

Income Statement

Eiken Chemical Co., Ltd. has shown a stable revenue base with a marginal growth of 1.22% from 2024 to 2025. Gross Profit Margin slightly decreased to 40.73% in 2025, indicating consistent production efficiency. However, the Net Profit Margin has decreased from 6.58% in 2024 to 5.50% in 2025, reflecting a decline in net profitability. The EBIT and EBITDA margins suggest operational efficiency, but the declining trend in EBIT margin needs attention.

Balance Sheet

The company's balance sheet is solid with a Debt-to-Equity ratio of 0.10, indicating low financial leverage. The Equity Ratio is high at 69.88%, showing a strong capital structure. However, the Return on Equity has decreased to 5.11% in 2025, suggesting reduced efficiency in generating profits from shareholders' equity. Overall, the balance sheet reflects financial stability with a significant equity base.

Cash Flow

Operating Cash Flow to Net Income ratio is robust at 2.71, indicating strong cash generation relative to net income. However, the Free Cash Flow to Net Income ratio has declined to 0.36, suggesting a decrease in cash available after capital expenditures. The Free Cash Flow Growth Rate has also significantly dropped, indicating potential cash flow strain in recent periods.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	41.22B	40.54B	40.05B	43.27B	43.00B	38.66B
Gross Profit	16.66B	16.51B	16.72B	20.51B	20.57B	18.53B
EBITDA	6.86B	5.56B	5.84B	9.73B	10.55B	8.58B
Net Income	2.34B	2.23B	2.63B	5.74B	6.22B	5.04B
Balance Sheet
Total Assets	59.50B	62.97B	62.25B	66.76B	63.02B	56.18B
Cash, Cash Equivalents and Short-Term Investments	4.67B	9.87B	16.31B	18.32B	16.12B	9.23B
Total Debt	3.00B	4.47B	4.33B	4.31B	4.19B	1.16B
Total Liabilities	17.74B	19.37B	16.28B	17.22B	17.22B	14.51B
Stockholders Equity	41.75B	43.60B	45.97B	49.53B	45.80B	41.67B
Cash Flow
Free Cash Flow	0.00	812.00M	1.72B	4.30B	2.88B	3.34B
Operating Cash Flow	0.00	6.03B	3.81B	7.58B	7.77B	5.45B
Investing Cash Flow	0.00	-4.50B	-2.22B	-316.00M	-5.04B	-2.19B
Financing Cash Flow	0.00	-4.86B	-6.69B	-2.10B	1.20B	-1.27B

Eiken Chemical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2407.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4549, the sentiment is Positive. The current price of 2407 is below the 20-day moving average (MA) of 3036.45, below the 50-day MA of 2705.28, and above the 200-day MA of 2403.56, indicating a neutral trend. The MACD of 59.28 indicates Positive momentum. The RSI at 51.55 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4549.

Eiken Chemical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6678	78 Outperform	¥21.29B	15.12	―	3.02%	-4.36%	-14.92%
6823	69 Neutral	¥35.33B	10.15	―	2.93%	6.72%	20.01%
4549	68 Neutral	¥96.14B	26.70	―	2.31%	4.36%	79.43%
6849	65 Neutral	¥256.92B	36.37	―	1.92%	4.31%	96.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6523	51 Neutral	¥129.39B	28.05	2.42%	3.73%	0.04%	―

Eiken Chemical Co., Ltd. Corporate Events

Eiken Chemical Overhauls Governance With New C-Suite Structure

Eiken Chemical will introduce a formal C-suite structure on April 1, 2026, creating roles including CEO, COO, CMSO, CTO, CPO, CFO, and CHRO to place domain experts at the center of core business functions. The company expects this governance shift to strengthen managerial foundations by improving decision quality, speeding execution, and enhancing expertise in operations, technology, marketing, production, finance, and human resources.

Under the new structure, President and CEO Yuji Segawa will also serve as CEO and COO, while several senior leaders are retitled to align with the new organization. Research and development, production, and sales units are being reorganized into headquarters functions with clearly defined chief roles, signaling a push for integrated management, stable supply, and sustained corporate value growth that may bolster competitiveness in the diagnostics sector.

The most recent analyst rating on (JP:4549) stock is a Buy with a Yen3647.00 price target. To see the full list of analyst forecasts on Eiken Chemical Co., Ltd. stock, see the JP:4549 Stock Forecast page.

Eiken Chemical Posts Strong Profit Surge, Lifts Dividend and Confirms Full-Year Outlook

Eiken Chemical reported consolidated net sales of ¥31.38 billion for the nine months ended December 31, 2025, up 2.4% year on year, with operating profit rising 5.5% to ¥2.78 billion and profit attributable to owners of parent jumping 75.8% to ¥3.72 billion, supported in part by a lower share count that also lifted basic earnings per share to ¥112.94. The company’s equity ratio improved to 72.5% and net assets per share increased, while it maintained its full-year forecast for FY2025 (ending March 31, 2026), targeting 4.1% sales growth and a 69.2% rise in full-year profit attributable to owners of parent, and plans to raise the annual dividend to ¥58 per share, signaling confidence in earnings resilience and a continued commitment to shareholder returns despite a projected decline in ordinary profit.

The most recent analyst rating on (JP:4549) stock is a Hold with a Yen2306.00 price target. To see the full list of analyst forecasts on Eiken Chemical Co., Ltd. stock, see the JP:4549 Stock Forecast page.